awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q50076626-8BF44633-2B1A-4768-A9CD-E85350758409
Q50076626-8BF44633-2B1A-4768-A9CD-E85350758409
BestRank
Statement
http://www.wikidata.org/entity/statement/Q50076626-8BF44633-2B1A-4768-A9CD-E85350758409
PARP inhibitors: Clinical utility and possibilities of overcoming resistance.
P2860
Q50076626-8BF44633-2B1A-4768-A9CD-E85350758409
BestRank
Statement
http://www.wikidata.org/entity/statement/Q50076626-8BF44633-2B1A-4768-A9CD-E85350758409
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
4f91435cda6fc03a4dc70c03cf77cf3d15ff8fe6
P2860
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.